Skip to main content

Free Content Pyrazinamide serum levels in childhood tuberculosis [Short communication]

Download Article:
 Download
(PDF 268.955078125 kb)
 
Pyrazinamide (PZA) is one of the first-line drugs in anti-tuberculosis treatment. In the present study, PZA serum levels in 34 children aged 1 to 14 years were measured either after oral application of PZA alone or after combination therapy with isoniazid and rifampicin. Serum levels did not differ statistically with age, in PZA monotherapy or in combination therapy. With a dosage of 30 mg/kg PZA, efficient serum levels were reached. Because PZA is distributed uniformly in the body, serum levels are related to body weight, and a dose of 30 mg/kg bodyweight is appropriate in children.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: childhood tuberculosis; pharmacokinetics; pyrazinamide; serum levels

Document Type: Short Communication

Affiliations: 1: Department of Paediatric Pneumology and Immunology, Helios Klinikum Emil von Behring, Chest Hospital Heckeshorn, Berlin, Germany 2: Department of Paediatric Pneumology and Immunology, Charité University Medical Center, Berlin, Germany 3: Department of Paediatric Pneumology and Immunology, Helios Klinikum Emil von Behring, Chest Hospital Heckeshorn, Berlin, Germany; and Department of Paediatric Pneumology and Immunology, Charité University Medical Center, Berlin, Germany

Publication date: 2008-09-01

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.

    Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more